Organization Overview
Historical Acquisition Tree
Alternative names
mirvetuximab soravtansine (Elahere) (2022 NDA)
Key: Immunogen (20) Acquired (1)
azacitidine (vidaza) (1 trial)
cantuzumab ravtansine (2 trials)
carboplatin (paraplatin) (3 trials)
Adenocarcinoma (Phase 2)
Adenocarcinoma, Clear Cell (Phase 2)
Carcinoma (Phase 1)
Carcinoma, Merkel Cell (Phase 1)
Carcinoma, Ovarian Epithelial (Phase 3)
Carcinosarcoma (Phase 1)
Celiac Disease (Phase 2)
Cystadenocarcinoma, Serous (Phase 2)
Endometrial Neoplasms (Phase 2)
Fallopian Tube Neoplasms (Phase 3)
Leukemia (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)
Leukemia, Lymphoid (Phase 1)
Leukemia, Myeloid (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Lung Neoplasms (Phase 2)
Lymphoma (Phase 2)
Lymphoma, B-Cell (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Mesothelioma (Phase 2)
Mixed Tumor, Mullerian (Phase 1)
Multiple Myeloma (Phase 1)
Myeloproliferative Disorders (Phase 1)
Neoplasms (Phase 1)
Neoplasms, Plasma Cell (Phase 1)
Ovarian Neoplasms (Phase 3)
Pancreatic Neoplasms (Phase 1)
Peritoneal Neoplasms (Phase 1)
Small Cell Lung Carcinoma (Phase 2)
Stomach Neoplasms (Phase 2)
